All In Biotech

Free tool

FAERS Monitor: Fotivda

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212904 or its brand name (Fotivda, Tivozanib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,610

Serious

603

37% of reports

Hospitalization

368

Death reported

159

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue316
  • diarrhoea196
  • blood pressure increased150
  • nausea142
  • disease progression139
  • decreased appetite135
  • dysphonia112
  • death106
  • asthenia93
  • off label use93
  • hypertension83
  • vomiting73
  • pain71
  • dyspnoea70
  • headache55

Reports by year received

View as table
YearReports
20116
20122
201314
20142
20151
20172
20185
20199
20205
2021349
2022581
2023230
202475
2025209
2026120

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,549 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dysphoniaSignal11225.121.02,566
disease progressionSignal13915.413.11,861
blood pressure increasedSignal15012.811.01,634
decreased appetiteSignal1357.66.5775
fatigueSignal3165.34.81,141
hypertensionSignal835.14.2274
diarrhoeaSignal1964.03.5446
astheniaSignal933.22.7144
nauseaSignal1422.32.0112
vomitingSignal732.01.638
dyspnoea701.61.316
death1061.61.325
pain711.51.212
off label use931.41.110
headache551.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.